Transcode Therapeutics, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
NASDAQ
S-1: TransCode Therapeutics Files for Resale of Common Stock and Warrants Following Private Placement
TransCode Therapeutics is registering the resale of common stock and warrants issued in a recent private placement, as the company continues to develop its oncology-focused platform.
NASDAQ
S-1/A: TransCode Therapeutics Announces Common Stock and Warrant Offering to Bolster Oncology Pipeline
TransCode Therapeutics is offering shares and warrants to fund its oncology platform, including its lead candidate TTX-MC138, while facing Nasdaq compliance challenges.
NASDAQ
TransCode Therapeutics implements a 1-for-40 reverse stock split and launches a public offering of common stock and warrants to advance its oncology-focused RNA therapeutic platform.
NASDAQ
TransCode Therapeutics is seeking to raise up to $7.5 million through a public offering of common stock and warrants to advance its oncology-focused RNA therapeutic programs.